Literature DB >> 35927263

TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening.

Miguel M Álvarez1, Josep Biayna1,2, Fran Supek3,4.   

Abstract

CRISPR/Cas9 gene editing can inactivate genes in a precise manner. This process involves DNA double-strand breaks (DSB), which may incur a loss of cell fitness. We hypothesize that DSB toxicity may be variable depending on the chromatin environment in the targeted locus. Here, by analyzing isogenic cell line pair CRISPR experiments jointly with previous screening data from across ~900 cell lines, we show that TP53-associated break toxicity is higher in genomic regions that harbor active chromatin, such as gene regulatory elements or transcription elongation histone marks. DSB repair pathway choice and DNA sequence context also associate with toxicity. We also show that, due to noise introduced by differential toxicity of sgRNA-targeted sites, the power of genetic screens to detect conditional essentiality is reduced in TP53 wild-type cells. Understanding the determinants of Cas9 cut toxicity will help improve design of CRISPR reagents to avoid incidental selection of TP53-deficient and/or DNA repair deficient cells.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35927263      PMCID: PMC9352712          DOI: 10.1038/s41467-022-32285-1

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   17.694


  78 in total

Review 1.  Integrating genetic approaches into the discovery of anticancer drugs.

Authors:  L H Hartwell; P Szankasi; C J Roberts; A W Murray; S H Friend
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

2.  Mutational signatures are markers of drug sensitivity of cancer cells.

Authors:  Jurica Levatić; Marina Salvadores; Francisco Fuster-Tormo; Fran Supek
Journal:  Nat Commun       Date:  2022-05-25       Impact factor: 17.694

3.  RNA-guided human genome engineering via Cas9.

Authors:  Prashant Mali; Luhan Yang; Kevin M Esvelt; John Aach; Marc Guell; James E DiCarlo; Julie E Norville; George M Church
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

4.  Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.

Authors:  Andrew J Aguirre; Robin M Meyers; Barbara A Weir; Francisca Vazquez; Cheng-Zhong Zhang; Uri Ben-David; April Cook; Gavin Ha; William F Harrington; Mihir B Doshi; Maria Kost-Alimova; Stanley Gill; Han Xu; Levi D Ali; Guozhi Jiang; Sasha Pantel; Yenarae Lee; Amy Goodale; Andrew D Cherniack; Coyin Oh; Gregory Kryukov; Glenn S Cowley; Levi A Garraway; Kimberly Stegmaier; Charles W Roberts; Todd R Golub; Matthew Meyerson; David E Root; Aviad Tsherniak; William C Hahn
Journal:  Cancer Discov       Date:  2016-06-03       Impact factor: 39.397

5.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Authors:  Fiona M Behan; Francesco Iorio; Gabriele Picco; Kosuke Yusa; Mathew J Garnett; Emanuel Gonçalves; Charlotte M Beaver; Giorgia Migliardi; Rita Santos; Yanhua Rao; Francesco Sassi; Marika Pinnelli; Rizwan Ansari; Sarah Harper; David Adam Jackson; Rebecca McRae; Rachel Pooley; Piers Wilkinson; Dieudonne van der Meer; David Dow; Carolyn Buser-Doepner; Andrea Bertotti; Livio Trusolino; Euan A Stronach; Julio Saez-Rodriguez
Journal:  Nature       Date:  2019-04-10       Impact factor: 49.962

6.  Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells.

Authors:  Francesco Piras; Michela Riba; Carolina Petrillo; Dejan Lazarevic; Ivan Cuccovillo; Sara Bartolaccini; Elia Stupka; Bernhard Gentner; Davide Cittaro; Luigi Naldini; Anna Kajaste-Rudnitski
Journal:  EMBO Mol Med       Date:  2017-09       Impact factor: 12.137

7.  Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.

Authors:  Anne Ramsay Bowden; David A Morales-Juarez; Matylda Sczaniecka-Clift; Maria Martin Agudo; Natalia Lukashchuk; John Christopher Thomas; Stephen P Jackson
Journal:  Elife       Date:  2020-05-22       Impact factor: 8.140

8.  The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.

Authors:  Vijayalakshmi Kari; Sanjay Kumar Raul; Jana Maria Henck; Julia Kitz; Frank Kramer; Robyn Laura Kosinsky; Nadine Übelmesser; Wael Yassin Mansour; Jessica Eggert; Melanie Spitzner; Zeynab Najafova; Holger Bastians; Marian Grade; Jochen Gaedcke; Florian Wegwitz; Steven A Johnsen
Journal:  Clin Epigenetics       Date:  2019-01-07       Impact factor: 6.551

9.  Integrated cross-study datasets of genetic dependencies in cancer.

Authors:  Clare Pacini; Joshua M Dempster; Isabella Boyle; Emanuel Gonçalves; Hanna Najgebauer; Emre Karakoc; Dieudonne van der Meer; Andrew Barthorpe; Howard Lightfoot; Patricia Jaaks; James M McFarland; Mathew J Garnett; Aviad Tsherniak; Francesco Iorio
Journal:  Nat Commun       Date:  2021-03-12       Impact factor: 14.919

10.  Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome.

Authors:  Phoebe C R Parrish; James D Thomas; Austin M Gabel; Shriya Kamlapurkar; Robert K Bradley; Alice H Berger
Journal:  Cell Rep       Date:  2021-08-31       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.